Priya Singhal - 05 Jan 2023 Form 3 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Development
Signature
/s/ Wendell Taylor, attorney-in-fact for Priya Singhal
Issuer symbol
BIIB
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
3
Filing time
17 Jan 2023, 15:53:21 UTC
Next filing
27 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIIB Common Stock 1,529 05 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 1,742 $0.000000 Direct F1
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 638 $0.000000 Direct F2
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 852 $0.000000 Direct F3
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 3,635 $0.000000 Direct F4
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 315 $0.000000 Direct F5
holding BIIB Restricted Stock Unit 05 Jan 2023 Common Stock 5,005 $0.000000 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2 This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3 This award was granted to the reporting person on December 8, 2021 and will vest in three equal installments on each anniversary of the grant date.
F4 This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date.
F5 This award was granted to the reporting person on July 1, 2020 and will vest in three equal installments on each anniversary of the grant date.
F6 This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date.